Stocktoria

Liminatus Pharma, Inc. LIMN

Nasdaq · stock · Biological Products, (No Diagnostic Substances) · website · IPO 2021-05-18

Liminatus Pharma, Inc. statistics & valuation

Market cap$5.3M

Market cap as of 2026-06-29. Multiples are price-derived and refreshed daily; everything else from the latest financial reports.

Profitability & efficiency

Gross margin (%)
20242025
Operating margin (%)
20242025
Return on equity (%)
20242025
Shares outstanding
17.5M 27.1M 20242025
Net debt ($)
20242025
Share buybacks ($)
20242025
Return on assets (%)
-65.60% -1990.40% 20242025
Free cash flow margin (%)
20242025
Debt / equity (×)
20242025
EPS ($)
-$0.20 -$0.43 20242025

Margins and returns computed from annual filings. Falling shares outstanding = buybacks; rising = dilution. Net debt = debt − cash (negative = net cash).

Key ratios (by fiscal year)

RatioFY2025FY2024
Return on assets-1990.4%-65.6%
Return on equity104.0%18.3%
Current ratio0.050.21

Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.